- Tilray Brands reported an adjusted EBITDA of $9.02 million for Q2, marking a decrease of 11% year-over-year, falling short of the estimated $11.6 million.
- The company achieved net revenue of $211.0 million, which represents an 8.7% increase from the previous year, though slightly below the expected $217 million.
- Cannabis revenue came in at $65.7 million, showing a 2% decline year-over-year, and missing the estimate of $66 million.
- Distribution revenue was $67.6 million, reflecting a modest 0.9% increase year-over-year, but did not meet the anticipated $68.5 million.
- Wellness revenue rose by 13% year-over-year, reaching $14.6 million, exceeding the estimate of $14 million.
- The company reported a loss per share of 10 cents, compared to 7 cents per share a year ago and greater than the estimated loss of 3.9 cents per share.
- Cash and cash equivalents grew by 32% year-over-year, totaling $189.7 million, but fell short of the projected $211.8 million.
- Analyst recommendations for Tilray are four buys, ten holds, and zero sells.
A look at Tilray Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 5 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
With a strong emphasis on value and growth potential within the pharmaceutical industry, Tilray Inc is positioned as a standout investment opportunity. Achieving a top score in the value category, the company showcases robust fundamentals and solid financial health. Coupled with a commendable growth score, Tilray Inc demonstrates promising prospects for long-term capital appreciation. Despite lower scores in dividend, resilience, and momentum, the company’s core focus on innovative cannabis-based medicines and products sets a positive tone for its future.
Operating globally and with a key focus on developing pharmaceutical solutions, Tilray Inc is a noteworthy player in the industry. With a growing presence and a dedication to providing high-quality drugs and products, the company is positioned to capture market share and establish itself as a key player in the pharmaceutical space. Investors seeking exposure to a forward-thinking company with strong value propositions and growth potential may find Tilray Inc an intriguing choice for long-term growth.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
